
Kyungdong Pharmaceutical and Asimov Complete Cell Line Development for Biosimilar Antibody
Kyungdong Pharmaceutical announced the successful completion of a cell line development campaign for a biosimilar antibody candidate through a collaboration with Asimov, a company specializing in artificial intelligence-driven synthetic biology platforms. The achievement represents a significant milestone in the development of next-generation biosimilar therapeutics.
The completed cell line development provides Kyungdong with a high-performing production platform that will enable the company to advance to subsequent stages of drug development, including process optimization, large-scale manufacturing, and eventual market commercialization. The partnership demonstrates how artificial intelligence and synthetic biology tools are increasingly being leveraged to accelerate the development timelines for complex biopharmaceutical products.













